{ "FullStudy":{ "Rank":217878, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01515657", "OrgStudyIdInfo":{ "OrgStudyId":"PL-ASA-004" }, "Organization":{ "OrgFullName":"PLx Pharma", "OrgClass":"INDUSTRY" }, "BriefTitle":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients", "OfficialTitle":"A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes" }, "StatusModule":{ "StatusVerifiedDate":"February 2016", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"January 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"June 2012", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"June 2012", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 13, 2012", "StudyFirstSubmitQCDate":"January 18, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 24, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"June 22, 2015", "ResultsFirstSubmitQCDate":"August 5, 2015", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"September 4, 2015", "ResultsFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"February 11, 2016", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"March 14, 2016", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"PLx Pharma", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Diabetes Mellitus, Type 2" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 3" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Crossover Assignment", "DesignPrimaryPurpose":"Prevention", "DesignMaskingInfo":{ "DesignMasking":"Single", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Outcomes Assessor" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"40", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"PL2200 Aspirin Capsules", "ArmGroupType":"Experimental", "ArmGroupDescription":"Investigational drug arm; crossover design", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: PL2200 Aspirin Capsules" ] } },{ "ArmGroupLabel":"Immediate-Release Aspirin Tablets", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Active comparator; crossover design", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Immediate-Release Aspirin Tablets" ] } },{ "ArmGroupLabel":"Enteric-coated aspirin caplets", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Active comparator; crossover design", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Enteric-coated aspirin caplets" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"PL2200 Aspirin Capsules", "InterventionDescription":"325 mg aspirin; once per day for 3 days", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "PL2200 Aspirin Capsules" ] } },{ "InterventionType":"Drug", "InterventionName":"Immediate-Release Aspirin Tablets", "InterventionDescription":"325 mg aspirin; once per day for 3 days", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Immediate-Release Aspirin Tablets" ] } },{ "InterventionType":"Drug", "InterventionName":"Enteric-coated aspirin caplets", "InterventionDescription":"325 mg aspirin; once per day for 3 days", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Enteric-coated aspirin caplets" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Time to 99% Inhibition of Serum Thromboxane (TxB2)", "PrimaryOutcomeDescription":"Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.", "PrimaryOutcomeTimeFrame":"4 days" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nAdults 21-79\nBody mass index (BMI) of 30-40 kg/m2\nNon-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of > 6.4% and/or fasting plasma glucose of >125 mg/dL or current anti-diabetic medication)\nAA-induced platelet aggregation response of >60% within 3 hours prior to initial dose of study drug administration\n\nExclusion Criteria:\n\nContraindications to aspirin\nPrevious history of vascular disease\nPatient requires insulin\nUse of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"21 Years", "MaximumAge":"79 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "LocationList":{ "Location":[ { "LocationFacility":"MedPace Clinical Pharmacology", "LocationCity":"Cincinnati", "LocationState":"Ohio", "LocationZip":"45212", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"28089180", "ReferenceType":"derived", "ReferenceCitation":"Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, Cryer B, Marathi U. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14;69(6):603-612. doi: 10.1016/j.jacc.2016.11.050. Epub 2017 Jan 11." } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"PL2200 Aspirin First, Then IR Aspirin Tablets, Then EC Aspirin", "FlowGroupDescription":"First Intervention Period:\n\nPL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nSecond Intervention Period:\n\nIR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nThird Intervention Period:\n\nEC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days" },{ "FlowGroupId":"FG001", "FlowGroupTitle":"IR Aspirin Tablets First, Then EC Aspirin, Then PL2200 Aspirin", "FlowGroupDescription":"First Intervention Period:\n\nIR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nSecond Intervention Period:\n\nEC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nThird Intervention Period:\n\nPL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days" },{ "FlowGroupId":"FG002", "FlowGroupTitle":"EC Aspirin First, Then PL2200 Aspirin, Then IR Aspirin Tablets", "FlowGroupDescription":"First Intervention Period:\n\nEC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nSecond Intervention Period:\n\nPL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days (after 2-week washout period)\n\nThird Intervention Period:\n\nIR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days" } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"First Intervention", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"13" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"12" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"0" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"0" } ] } } ] } },{ "FlowPeriodTitle":"Second Intervention", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"12" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"11" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"0" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"0" } ] } } ] } },{ "FlowPeriodTitle":"Third Intervention", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"11" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"13" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"11" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"13" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"0" },{ "FlowAchievementGroupId":"FG002", "FlowAchievementNumSubjects":"0" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"All Study Participants", "BaselineGroupDescription":"All patients that received at least 1 dose of study drug under the study protocol." } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"40" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"52.9", "BaselineMeasurementSpread":"10.12" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"14" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"26" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Time to 99% Inhibition of Serum Thromboxane (TxB2)", "OutcomeMeasureDescription":"Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.", "OutcomeMeasurePopulationDescription":"Pharmacodynamic (PD) Evaluable Population for Time to 99% Inhibition", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Hours", "OutcomeMeasureTimeFrame":"4 days", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"PL2200 Aspirin Capsules", "OutcomeGroupDescription":"Investigational drug arm; crossover design\n\nPL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Immediate-Release Aspirin Tablets", "OutcomeGroupDescription":"Active comparator; crossover design\n\nImmediate-Release Aspirin Tablets: 325 mg aspirin; once per day for 3 days" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Enteric-coated Aspirin Caplets", "OutcomeGroupDescription":"Active comparator; crossover design\n\nEnteric-coated aspirin caplets: 325 mg aspirin; once per day for 3 days" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"35" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"35" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"35" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12.36", "OutcomeMeasurementSpread":"23.42" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"16.65", "OutcomeMeasurementSpread":"27.21" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"48.64", "OutcomeMeasurementSpread":"31.20" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"0", "EventsDescription":"modified Intent-to-Treat population: all patients that received at least 1 dose of study drug under the study protocol", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"PL2200 Aspirin Capsules", "EventGroupDescription":"Investigational drug arm; crossover design\n\nPL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"38", "EventGroupOtherNumAffected":"2", "EventGroupOtherNumAtRisk":"38" },{ "EventGroupId":"EG001", "EventGroupTitle":"Immediate-Release Aspirin Tablets", "EventGroupDescription":"Active comparator; crossover design\n\nImmediate-Release Aspirin Tablets: 325 mg aspirin; once per day for 3 days", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"40", "EventGroupOtherNumAffected":"4", "EventGroupOtherNumAtRisk":"40" },{ "EventGroupId":"EG002", "EventGroupTitle":"Enteric-coated Aspirin Caplets", "EventGroupDescription":"Active comparator; crossover design\n\nEnteric-coated aspirin caplets: 325 mg aspirin; once per day for 3 days", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"38", "EventGroupOtherNumAffected":"7", "EventGroupOtherNumAtRisk":"38" } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Nausea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"2", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"38" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"40" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"38" } ] } },{ "OtherEventTerm":"Viral Infection", "OtherEventOrganSystem":"Infections and infestations", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"38" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"40" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumEvents":"2", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"38" } ] } },{ "OtherEventTerm":"Dizziness", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"38" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"40" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumEvents":"2", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"38" } ] } },{ "OtherEventTerm":"Headache", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"38" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"2", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"40" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumEvents":"2", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"38" } ] } } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictionType":"OTHER", "AgreementRestrictiveAgreement":"Yes", "AgreementOtherDetails":"Standard confidentiality agreement" }, "PointOfContact":{ "PointOfContactTitle":"Ronald Zimmerman", "PointOfContactOrganization":"PLx Pharma", "PointOfContactEMail":"ron.zimmerman@plxpharma.com", "PointOfContactPhone":"1-713-842-1249", "PointOfContactPhoneExt":"205" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000001241", "InterventionMeshTerm":"Aspirin" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000894", "InterventionAncestorTerm":"Anti-Inflammatory Agents, Non-Steroidal" },{ "InterventionAncestorId":"D000018712", "InterventionAncestorTerm":"Analgesics, Non-Narcotic" },{ "InterventionAncestorId":"D000000700", "InterventionAncestorTerm":"Analgesics" },{ "InterventionAncestorId":"D000018689", "InterventionAncestorTerm":"Sensory System Agents" },{ "InterventionAncestorId":"D000018373", "InterventionAncestorTerm":"Peripheral Nervous System Agents" },{ "InterventionAncestorId":"D000045505", "InterventionAncestorTerm":"Physiological Effects of Drugs" },{ "InterventionAncestorId":"D000000893", "InterventionAncestorTerm":"Anti-Inflammatory Agents" },{ "InterventionAncestorId":"D000018501", "InterventionAncestorTerm":"Antirheumatic Agents" },{ "InterventionAncestorId":"D000005343", "InterventionAncestorTerm":"Fibrinolytic Agents" },{ "InterventionAncestorId":"D000050299", "InterventionAncestorTerm":"Fibrin Modulating Agents" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" },{ "InterventionAncestorId":"D000010975", "InterventionAncestorTerm":"Platelet Aggregation Inhibitors" },{ "InterventionAncestorId":"D000016861", "InterventionAncestorTerm":"Cyclooxygenase Inhibitors" },{ "InterventionAncestorId":"D000004791", "InterventionAncestorTerm":"Enzyme Inhibitors" },{ "InterventionAncestorId":"D000058633", "InterventionAncestorTerm":"Antipyretics" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M3129", "InterventionBrowseLeafName":"Aspirin", "InterventionBrowseLeafAsFound":"Aspirin", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2799", "InterventionBrowseLeafName":"Anti-Inflammatory Agents, Non-Steroidal", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2798", "InterventionBrowseLeafName":"Anti-Inflammatory Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2613", "InterventionBrowseLeafName":"Analgesics", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19370", "InterventionBrowseLeafName":"Analgesics, Non-Narcotic", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19188", "InterventionBrowseLeafName":"Antirheumatic Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M7056", "InterventionBrowseLeafName":"Fibrinolytic Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M12448", "InterventionBrowseLeafName":"Platelet Aggregation Inhibitors", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M17792", "InterventionBrowseLeafName":"Cyclooxygenase Inhibitors", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M27763", "InterventionBrowseLeafName":"Antipyretics", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"Antipy", "InterventionBrowseBranchName":"Antipyretics" },{ "InterventionBrowseBranchAbbrev":"Infl", "InterventionBrowseBranchName":"Anti-Inflammatory Agents" },{ "InterventionBrowseBranchAbbrev":"ARhu", "InterventionBrowseBranchName":"Antirheumatic Agents" },{ "InterventionBrowseBranchAbbrev":"FiAg", "InterventionBrowseBranchName":"Fibrinolytic Agents" },{ "InterventionBrowseBranchAbbrev":"Analg", "InterventionBrowseBranchName":"Analgesics" },{ "InterventionBrowseBranchAbbrev":"PlAggInh", "InterventionBrowseBranchName":"Platelet Aggregation Inhibitors" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000003924", "ConditionMeshTerm":"Diabetes Mellitus, Type 2" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000003920", "ConditionAncestorTerm":"Diabetes Mellitus" },{ "ConditionAncestorId":"D000044882", "ConditionAncestorTerm":"Glucose Metabolism Disorders" },{ "ConditionAncestorId":"D000008659", "ConditionAncestorTerm":"Metabolic Diseases" },{ "ConditionAncestorId":"D000004700", "ConditionAncestorTerm":"Endocrine System Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M5702", "ConditionBrowseLeafName":"Diabetes Mellitus, Type 2", "ConditionBrowseLeafAsFound":"Diabetes Mellitus, Type 2", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M5698", "ConditionBrowseLeafName":"Diabetes Mellitus", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10222", "ConditionBrowseLeafName":"Metabolic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M23990", "ConditionBrowseLeafName":"Glucose Metabolism Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M6445", "ConditionBrowseLeafName":"Endocrine System Diseases", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC18", "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases" },{ "ConditionBrowseBranchAbbrev":"BC19", "ConditionBrowseBranchName":"Gland and Hormone Related Diseases" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" } ] } } } } } }